Cartilage Repair — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cartilage repair in regenerative medicine encompasses a spectrum of biological strategies to restore hyaline articular cartilage lost to traumatic injury, osteochondritis dissecans (OCD), or early focal degenerative disease. Hyaline cartilage is uniquely vulnerable because it is avascular, aneural, and alymphatic—lacking the vascularity necessary for conventional wound healing responses. Chondrocytes, the resident cells of cartilage, have extremely limited proliferative capacity in mature cartilage, meaning even small defects rarely heal spontaneously and tend to propagate toward generalized osteoarthritis over time. Marrow stimulation techniques such as microfracture and drilling create channels through subchondral bone, allowing marrow-derived mesenchymal stem cells to populate the defect and form fibrocartilaginous repair tissue—mechanically inferior to native hyaline cartilage but technically simpler to perform. Cell-based therapies aim to produce repair tissue with biomechanical and histological characteristics closer to native cartilage. Autologous chondrocyte implantation (ACI), first performed by Brittberg et al. in 1994, involves harvesting the patient's own chondrocytes arthroscopically, expanding them in culture over 4-6 weeks, and reimplanting them under a periosteal or collagen membrane cover. The second-generation matrix-induced ACI (MACI) technique seeds expanded chondrocytes onto a resorbable porcine collagen membrane that simplifies surgical technique and reduces periosteal-related complications. Osteochondral autograft transfer systems (OATS/mosaicplasty) harvest cylindrical osteochondral plugs from non-load-bearing regions and transfer them to the defect site, providing immediate structural support with native hyaline cartilage. Allograft osteochondral transplantation uses fresh cadaveric tissue for larger defects.

Biological cartilage repair is indicated for specific types of cartilage pathology in appropriate patient populations. The primary indication is focal, full-thickness chondral or osteochondral defects classified as Outerbridge grade III (partial loss of surface contour with a defect diameter ≤1.5 cm and softening without surface disruption) or grade IV (complete erosion of cartilage with exposed subchondral bone). Specific conditions include traumatic chondral defects following sports injuries, motor vehicle accidents, or falls—frequently seen in the medial femoral condyle, lateral femoral condyle, patella, and trochlea of the knee. Osteochondritis dissecans (OCD) represents a distinct condition affecting adolescents and young adults in whom a fragment of cartilage and its underlying bone becomes partially or completely detached from the joint surface; unstable OCD lesions in skeletally mature patients are primary candidates for MACI or OATS. Talar dome osteochondral defects (ankle) account for a significant proportion of cartilage repair cases, particularly post-ankle sprains, with OATS and ACI both used depending on lesion size and access. Patellofemoral chondral lesions at the patella or trochlea, often presenting as anterior knee pain in young active individuals, are treated with ACI/MACI when conservative measures fail. Shoulder glenohumeral cartilage defects in young patients sustaining traumatic instability episodes benefit from cartilage repair. Early focal osteoarthritis isolated to one compartment in a patient with otherwise normal joint alignment and ligamentous stability is a carefully selected indication.

Careful patient selection determines the success of cartilage repair procedures. Ideal candidates for ACI/MACI are active patients typically aged 15-50 years (though experienced surgeons may extend to 55-60 for well-selected cases) with symptomatic focal chondral defects 2-10 cm² in size, confirmed on MRI (T2-weighted cartilage sequences, T2-mapping, or dGEMRIC for biochemical cartilage mapping) and arthroscopic evaluation. Body mass index should ideally be below 35 kg/m² to minimize biomechanical overloading of the repair site. Limb mechanical alignment must be normal or correctable: varus malalignment exceeding 5° in a medial compartment defect requires concomitant or staged high tibial osteotomy. Ligamentous stability is essential—ACL or PCL deficiency must be reconstructed before or simultaneously with cartilage repair. Absolute contraindications include established generalized (tricompartmental) osteoarthritis, inflammatory arthropathy (rheumatoid, psoriatic, ankylosing spondylitis), active septic arthritis, prior total knee arthroplasty, and severe systemic illness precluding surgery and anesthesia. Relative contraindications include previous failed cartilage repair (though re-do ACI is possible in selected cases), multiple lesions (feasible but technically demanding), BMI above 40, and significant subchondral bone loss requiring bone grafting as a first stage. Pre-operative workup includes weight-bearing full-length leg alignment radiographs, knee MRI with cartilage protocol, and arthroscopic assessment confirming defect size and surrounding cartilage health. Patient motivation and commitment to a 12-18 month structured rehabilitation program are essential non-anatomical eligibility criteria.

Biological cartilage repair procedures offer durable symptom improvement and cartilage restoration superior to marrow stimulation in appropriately selected patients. ACI/MACI long-term outcomes: the landmark SUMMIT RCT compared MACI versus microfracture in 144 patients with symptomatic knee cartilage defects, demonstrating statistically significant superiority of MACI in KOOS Pain and KOOS Symptoms scores at 2 years, with 75% of MACI patients achieving clinically meaningful improvement versus 53% with microfracture. Multiple registry studies confirm 70-85% good to excellent clinical outcomes at 5-10 years post-MACI, with MRI evidence of complete or near-complete defect fill in 65-80% of cases and histological evidence of hyaline-like repair cartilage on biopsy. For defects larger than 4 cm², MACI demonstrates clear superiority over microfracture, which deteriorates more rapidly under sustained biomechanical loading. OATS outcomes: for smaller defects (1.5-4 cm²), OATS achieves 80-90% good or excellent outcomes at 5 years using ICRS or KOOS scoring, with the advantage of immediate implantation of mature hyaline cartilage without a cell culture waiting period. International Cartilage Repair Society (ICRS) data on 1,363 ACI cases report 76% overall good/excellent outcomes at 5-year follow-up. The most clinically significant benefit for younger patients is delay or prevention of total knee replacement progression—cartilage repair may provide 10-15 years of improved function before arthroplasty is required in optimally managed patients.

Cartilage repair procedures carry surgical risks and procedure-specific complications that must be comprehensively discussed with patients prior to commitment. For ACI and MACI: periosteal or membrane hypertrophy and delamination remains the most significant procedure-specific complication, occurring in 5-25% (periosteal hypertrophy was more common with first-generation periosteal-cover ACI; significantly reduced with MACI membrane). Incomplete defect fill on MRI affects 15-25% of patients and correlates with lower clinical scores, though isolated incomplete fill without clinical symptoms does not necessitate re-intervention. Arthrofibrosis—excessive intra-articular scar formation limiting joint range of motion—develops in 5-8% and may require arthroscopic release. Graft delamination (separation of the seeded membrane from the defect bed) occurs in 3-7% and typically requires revision surgery. Treatment failure requiring conversion to arthroplasty occurs in approximately 10-15% at 5 years and 20-25% at 10 years across large registry datasets, particularly in older patients with pre-existing subchondral bone changes. For OATS: donor site morbidity at the harvest site in the trochlea—including pain, cartilage loss, and occasional donor site cyst formation—affects 5-10% of patients. Incongruent cartilage height at the graft-host junction ('proud' or 'sunken' graft) can lead to mechanical symptoms and chondral damage at the opposing surface. For all cartilage procedures: general surgical risks include infection (<1%), deep vein thrombosis (<2%), hematoma, wound complications, and anesthetic risks. Rehabilitation non-compliance is a significant risk factor for poor outcomes—protected weight-bearing for 6-8 weeks must be strictly observed.

Cartilage repair procedure costs encompass two surgical episodes for cell-based techniques (harvest arthroscopy and implantation), cell culture laboratory fees, implant costs, operating theater, anesthesia, hospitalization, and the crucial 12-18 month physiotherapy rehabilitation program. In India, MACI cartilage repair at tertiary orthopedic centers (Kokilaben Dhirubhai Ambani Hospital Mumbai, Fortis Hospitals, Apollo, AIIMS) costs $5,000-15,000 USD for the complete procedure including both surgical stages and hospital stay. OATS/mosaicplasty in India is available at $3,000-8,000. Thailand charges $8,000-18,000 for MACI at internationally accredited centers in Bangkok. Turkey provides cartilage repair at $6,000-12,000 (MACI) at sports medicine-specialized hospitals. South Korea's internationally recognized sports medicine and orthopedic centers charge $10,000-20,000. In the United States, MACI (Vericel Corporation's FDA-approved product) costs $25,000-60,000 inclusive of the cell culture product ($41,250 list price per cm² of membrane), both surgical procedures, and facility fees; many major US insurance plans cover MACI for FDA-approved indications since 2016 approval. United Kingdom NHS covers ACI/MACI through NICE technology appraisal TA477 for symptomatic articular cartilage defects of the knee; private UK costs reach £12,000-35,000. Germany and France cover cartilage repair through statutory health insurance. Australia charges $18,000-40,000 at private hospitals with partial Medicare rebate. Rehabilitation costs of $2,000-8,000 should be factored into total cost estimates.

Cartilage repair procedures are selected based on defect size, depth, location, patient age, and activity level.

Grade 1-2 Defects (Partial Thickness) — Conservative: - Viscosupplementation, PRP injections, physiotherapy - Activity modification and load management

Grade 3-4 Defects (Full Thickness) — Surgical Options: - Microfracture: Awl penetration of subchondral bone; suitable for defects <2cm²; forms fibrocartilage (type I collagen) rather than hyaline cartilage; best results in younger (<40) patients; declining use as superior techniques emerge - Osteochondral Autograft Transfer (OATS/mosaicplasty): Harvests cylindrical osteochondral plugs from low-weight-bearing regions of the same knee and transfers to defect; ideal for defects 1-4cm²; preserves native hyaline cartilage surface; donor site morbidity limits volume - Autologous Chondrocyte Implantation (ACI/MACI): Two-stage: arthroscopic biopsy of chondrocytes, culture expansion (3-4 weeks), surgical implantation under periosteal or collagen membrane patch. MACI (Matrix-induced ACI): cells seeded on a collagen scaffold — single-step arthroscopic implantation possible. Best for large defects (>2-4cm²); young (<50), active patients - Osteochondral Allograft (OCA): Fresh allograft osteochondral plug from donor knee; for very large defects (>4cm²) or failed prior surgery; requires tissue banking and matching; limited availability - Particulated Juvenile Articular Cartilage (PJAC — DeNovo NT): Minced juvenile donor cartilage implanted with fibrin glue; one-stage procedure; emerging evidence

Scaffold-Based and Regenerative: - Aragonite scaffold (CartiHeal): FDA-approved 2021; off-the-shelf biphasic aragonite coral scaffold implanted into osteochondral defect; significant radiological and clinical improvement at 5 years (NCT01282398) - TruFit: Resorbable biphasic scaffold for backfill of OATS donor sites; limited evidence - BST-CarGel + microfracture: Chitosan-based scaffold enhancing microfracture clot quality; improves fibrocartilage quality

Cartilage repair requires a strict, staged rehabilitation protocol to allow tissue integration and prevent graft failure.

Phase 1 (Weeks 0-6 post-MACI/OATS): - Non-weight-bearing or toe-touch weight-bearing with crutches - Continuous passive motion (CPM) machine: 4-6 hours/day in hospital; promotes graft integration - No direct loading of the repair site - Passive range of motion exercises

Phase 2 (Weeks 6-12): - Progressive weight-bearing: full weight-bearing by week 8-12 - Pool therapy: aquatic walking and cycling — reduces load while maintaining movement - Begin quadriceps strengthening

Phase 3 (Months 3-6): - Gym-based rehabilitation: leg press, cycling, swimming - No impact activities until at least 6 months - Proprioception and balance training

Phase 4 (Months 6-12): - Running reintroduction: straight-line running from month 6-9 if asymptomatic - Return to sport: typically month 12-18 for competitive athletes

MRI Assessment: - MRI at 6 and 12 months: assess MOCART score (Magnetic Resonance Observation of Cartilage Repair Tissue): filling, integration, surface, signal intensity - Full maturation of repair tissue: 12-24 months

Outcome Assessment: - KOOS, IKDC, Lysholm scores at 6 months, 1 year, 2 years, 5 years

When surgical cartilage repair is not feasible or has failed, several alternatives manage symptoms and delay further deterioration.

Biological Injectables: - PRP (Platelet-Rich Plasma): Intra-articular injection series (3 injections over 3 weeks); reduces pain and improves function for 6-12 months; suitable when surgery is declined or patient is not yet at surgical threshold - BMAC (Bone Marrow Aspirate Concentrate): One-time injection; emerging evidence for contained cartilage defects - Hyaluronic acid viscosupplementation: Symptomatic relief for 3-6 months; limited evidence for actual cartilage preservation

Joint Arthroplasty: - For patients too old, sedentary, or with OA too extensive for cartilage repair: total or unicompartmental knee arthroplasty provides excellent pain relief and function without cartilage restoration

Emerging Cell Therapies: - Allogeneic chondrocyte products: Ready-to-use off-the-shelf chondrocytes (RevaFlex/IMPACT — Dutch trials); single-stage procedure; regulatory approval progressing - Induced pluripotent stem cell (iPSC)-derived chondrocytes: Theoretically unlimited cell source; clinical trials beginning; potential for off-the-shelf cartilage repair - Nanotechnology-enhanced scaffolds: Electrospun nanofibrous scaffolds mimicking cartilage ECM architecture; improved chondrocyte attachment and differentiation in vitro; translating to clinical trials

Load Management and Bracing: - Knee unloader braces (valgus or varus correction): redistribute load away from damaged compartment - Osteotomy (HTO, DFO): realigns the mechanical axis to unload the damaged compartment — provides a biological environment for repair tissue to mature